{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T04:02:38Z","timestamp":1794283358831,"version":"4.9.0"},"reference-count":26,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"8","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2018,3,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>In the ASPIRE study of carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide plus dexamethasone (Rd) in patients with relapsed or refractory multiple myeloma, progression-free survival was significantly improved in the carfilzomib group (hazard ratio, 0.69; two-sided P &lt; .001). This prespecified analysis reports final overall survival (OS) data and updated safety results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Adults with relapsed multiple myeloma (one to three prior lines of therapy) were eligible and randomly assigned at a one-to-one ratio to receive KRd or Rd in 28-day cycles until withdrawal of consent, disease progression, or occurrence of unacceptable toxicity. After 18 cycles, all patients received Rd only. Progression-free survival was the primary end point; OS was a key secondary end point. OS was compared between treatment arms using a stratified log-rank test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median OS was 48.3 months (95% CI, 42.4 to 52.8 months) for KRd versus 40.4 months (95% CI, 33.6 to 44.4 months) for Rd (hazard ratio, 0.79; 95% CI, 0.67 to 0.95; one-sided P = .0045). In patients receiving one prior line of therapy, median OS was 11.4 months longer for KRd versus Rd; it was 6.5 months longer for KRd versus Rd among patients receiving \u2265 two prior lines of therapy. Rates of treatment discontinuation because of adverse events (AEs) were 19.9% (KRd) and 21.5% (Rd). Grade \u2265 3 AE rates were 87.0% (KRd) and 83.3% (Rd). Selected grade \u2265 3 AEs of interest (grouped terms; KRd v Rd) included acute renal failure (3.8% v 3.3%), cardiac failure (4.3% v 2.1%), ischemic heart disease (3.8% v 2.3%), hypertension (6.4% v 2.3%), hematopoietic thrombocytopenia (20.2% v 14.9%), and peripheral neuropathy (2.8% v 3.1%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>KRd demonstrated a statistically significant and clinically meaningful reduction in the risk of death versus Rd, improving survival by 7.9 months. The KRd efficacy advantage is most pronounced at first relapse.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.2017.76.5032","type":"journal-article","created":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T15:59:38Z","timestamp":1516204778000},"page":"728-734","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":265,"title":["Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma"],"prefix":"10.1200","volume":"36","author":[{"given":"David S.","family":"Siegel","sequence":"first","affiliation":[{"name":"David S. Siegel, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; Meletios A. Dimopoulos, National and Kapodistrian University of Athens, Athens, Greece; Heinz Ludwig, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria; Thierry Facon, H\u00f4pital Claude Huriez, Centre Hospitalier R\u00e9gional Universitaire de Lille, Lille, France; Hartmut Goldschmidt, Heidelberg Medical University and National Center of Tumor Diseases, Heidelberg, Germany; Andrzej..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"David S. Siegel, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; Meletios A. Dimopoulos, National and Kapodistrian University of Athens, Athens, Greece; Heinz Ludwig, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria; Thierry Facon, H\u00f4pital Claude Huriez, Centre Hospitalier R\u00e9gional Universitaire de Lille, Lille, France; Hartmut Goldschmidt, Heidelberg Medical University and National Center of Tumor Diseases, Heidelberg, Germany; Andrzej..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Ludwig","sequence":"additional","affiliation":[{"name":"David S. Siegel, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; Meletios A. Dimopoulos, National and Kapodistrian University of Athens, Athens, Greece; Heinz Ludwig, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria; Thierry Facon, H\u00f4pital Claude Huriez, Centre Hospitalier R\u00e9gional Universitaire de Lille, Lille, France; Hartmut Goldschmidt, Heidelberg Medical University and National Center of Tumor Diseases, Heidelberg, Germany; Andrzej..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Facon","sequence":"additional","affiliation":[{"name":"David S. Siegel, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; Meletios A. Dimopoulos, National and Kapodistrian University of Athens, Athens, Greece; Heinz Ludwig, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria; Thierry Facon, H\u00f4pital Claude Huriez, Centre Hospitalier R\u00e9gional Universitaire de Lille, Lille, France; Hartmut Goldschmidt, Heidelberg Medical University and National Center of Tumor Diseases, Heidelberg, Germany; Andrzej..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[{"name":"David S. Siegel, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; Meletios A. Dimopoulos, National and Kapodistrian University of Athens, Athens, Greece; Heinz Ludwig, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria; Thierry Facon, H\u00f4pital Claude Huriez, Centre Hospitalier R\u00e9gional Universitaire de Lille, Lille, France; Hartmut Goldschmidt, Heidelberg Medical University and National Center of Tumor Diseases, Heidelberg, Germany; Andrzej..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Jakubowiak","sequence":"additional","affiliation":[{"name":"David S. Siegel, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; Meletios A. Dimopoulos, National and Kapodistrian University of Athens, Athens, Greece; Heinz Ludwig, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria; Thierry Facon, H\u00f4pital Claude Huriez, Centre Hospitalier R\u00e9gional Universitaire de Lille, Lille, France; Hartmut Goldschmidt, Heidelberg Medical University and National Center of Tumor Diseases, Heidelberg, Germany; Andrzej..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"San-Miguel","sequence":"additional","affiliation":[{"name":"David S. Siegel, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; Meletios A. Dimopoulos, National and Kapodistrian University of Athens, Athens, Greece; Heinz Ludwig, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria; Thierry Facon, H\u00f4pital Claude Huriez, Centre Hospitalier R\u00e9gional Universitaire de Lille, Lille, France; Hartmut Goldschmidt, Heidelberg Medical University and National Center of Tumor Diseases, Heidelberg, Germany; Andrzej..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Obreja","sequence":"additional","affiliation":[{"name":"David S. Siegel, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; Meletios A. Dimopoulos, National and Kapodistrian University of Athens, Athens, Greece; Heinz Ludwig, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria; Thierry Facon, H\u00f4pital Claude Huriez, Centre Hospitalier R\u00e9gional Universitaire de Lille, Lille, France; Hartmut Goldschmidt, Heidelberg Medical University and National Center of Tumor Diseases, Heidelberg, Germany; Andrzej..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Blaedel","sequence":"additional","affiliation":[{"name":"David S. Siegel, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; Meletios A. Dimopoulos, National and Kapodistrian University of Athens, Athens, Greece; Heinz Ludwig, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria; Thierry Facon, H\u00f4pital Claude Huriez, Centre Hospitalier R\u00e9gional Universitaire de Lille, Lille, France; Hartmut Goldschmidt, Heidelberg Medical University and National Center of Tumor Diseases, Heidelberg, Germany; Andrzej..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Keith","family":"Stewart","sequence":"additional","affiliation":[{"name":"David S. Siegel, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; Meletios A. Dimopoulos, National and Kapodistrian University of Athens, Athens, Greece; Heinz Ludwig, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria; Thierry Facon, H\u00f4pital Claude Huriez, Centre Hospitalier R\u00e9gional Universitaire de Lille, Lille, France; Hartmut Goldschmidt, Heidelberg Medical University and National Center of Tumor Diseases, Heidelberg, Germany; Andrzej..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.307"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.867"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1105202"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30578-8"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-707596"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14549"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.31"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.122"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.9648"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-2009-2_1"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/70.3.659"},{"key":"B16","volume-title":"Modelling Survival Data in Medical Research","author":"Collett D","year":"2003","edition":"2"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.147"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14787"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.01.003"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-726703"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.01.008"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/10245332.2017.1328165"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2014.02.005"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2017.76.5032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T05:55:43Z","timestamp":1653803743000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2017.76.5032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,10]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,3,10]]}},"alternative-id":["10.1200\/JCO.2017.76.5032"],"URL":"https:\/\/doi.org\/10.1200\/jco.2017.76.5032","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,10]]},"assertion":[{"value":"2018-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}